-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – 6MW-3211 in Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - 6MW-3211 in Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. 6MW-3211 in Lymphoma Drug Details: 6MW-3211 is under development for the treatment...
-
Product Insights
Ischemia Reperfusion Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Ischemia Reperfusion Injury - Drugs In Development, 2023’, provides an overview of the Ischemia Reperfusion Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ischemia Reperfusion Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2023
Global Markets Direct’s, ‘Acute Renal Failure (ARF) (Acute Kidney Injury) - Drugs In Development, 2023’, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Myocardial Infarction – Drugs In Development, 2023
Global Markets Direct’s, ‘Myocardial Infarction - Drugs In Development, 2023’, provides an overview of the Myocardial Infarction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Metastatic Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Metastatic Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Metastatic Colorectal Cancer Drug Details: Azenosertib (ZNC-3) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Triple-Negative Breast Cancer (TNBC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Spartalizumab (PDR-001) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tremelimumab in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tremelimumab in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Tremelimumab (Imjudo) is a human monoclonal monospecific...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vanadis-02 in Burns
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Vanadis-02 in Burns Drug Details:Vanadis-02 is under development for the treatment of second and third-degree burns....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vanadis-03 in Ischemia Reperfusion Injury
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Vanadis-03 in Ischemia Reperfusion InjuryDrug Details:Vanadis-03 is under development for the treatment of acute renal failure...